🗂️

Archived grant — no longer open

This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.

grant

Project 2

Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Sept 2019Deadline 14 Sept 2025 ⚠️
NIHUS FederalResearch GrantFY2024AccelerationAtrophicAtrophyAutoimmune StatusAutoimmunityBehavioralBiologicalBiological MarkersBiologyBlood PlasmaBrainBrain Nervous SystemC9ORF72CharacteristicsClinicalClinical TrialsClinical Trials DesignCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalDataDiseaseDisease ProgressionDisorderDisturbance in cognitionEncephalonEnrollmentFTLDFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationFutureGene variantGenesGeneticGenetic AlterationGenetic ChangeGenetic defectGoalsImageImmune Cell ActivationImmune MarkersImmunologic MarkersImpaired cognitionImpairmentIndividualInflammationLightLinkLiquid substanceLongitudinal StudiesMR ImagingMR TomographyMRIMRIsMT-bound tauMagnetic Resonance ImagingMeasurementMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMethodsMulti-Institutional Clinical TrialMulti-center clinical trialMulti-site clinical trialMulticenter clinical trialMultisite clinical trialMutationNMR ImagingNMR TomographyNorth AmericaNuclear Magnetic Resonance ImagingOutcomeOutcome MeasureParticipantPathologyPatient SelectionPatientsPatternPhenotypePhotoradiationPlasmaPlasma SerumPopulationProteinsReticuloendothelial System, Serum, PlasmaRiskSafetySample SizeSeverity of illnessSurrogate End PointsSurrogate EndpointSyndromeTAR DNA-binding protein 43TDP-43TDP43TestingTherapeuticTimeZeugmatographyallele variantallelic variantbehavioral variant FTDbehavioral variant frontotemporal degenerationbehavioral variant frontotemporal dementiabio-markersbiologicbiologic markerbiomarkerbvFTDchromosome 9 open reading frame 72clinical predictorsclinical trial enrollmentclinical trial readinesscognitive dysfunctioncognitive lossdesigndesigningdisease severitydrug developmentenrollfluidgenetic variantgenome mutationgenomic variantimagingimmune activationimmune-based biomarkersimmunological biomarkersimmunological markersimprovedliquidlong-term studylongitudinal outcome studieslongterm studymeasurable outcomemicrotubule bound taumicrotubule-bound taumolecular pathologymolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmotor diseasemotor disordermotor dysfunctionmulti-modalitymultimodalityneurofilamentneuropathologicneuropathologicalneuropathologyoutcome measurementparticipant enrollmentpatient enrollmentpatient populationpatient stratificationpolygenic risk scoreprotein TDP-43protein TDP43rate of changerecruitresponsestratified patienttautau Proteinstau factortherapeutic targettooltreatment effecttrial designτ Proteins

Applications closed.

Description preview

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: Project 2
Improvements in understanding the biology of FTLD, combined with revolutionary advancements in drug
development, have created new compounds that can alter the fundamental biological mechanisms that cause
FTLD. FTLD is most commonly associated with either underlying tau (FTLD-tau) or TAR DNA…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in UNITED STATES🏷 More NIH opportunities🏷 More US Federal opportunities🏷 More Research Grant opportunities🏢 All nih_reporter opportunities